In comparison, there are studies suggesting that HE4 could be used as an independent biomarker, in both diagnosis and prognosis of EOC and endometrial cancers.[8,9] It has also been approved by the United States of America (USA), Food and Drug Administration (FDA) as a biomarker to monitor patients with epithelial ovarian cancer.[10] It is observed that in normal tissue, HE4 is restricted to expression by tissue in the reproductive tract and respiratory epithelium.[11] However, HE4 is far from being exclusive to the aforementioned tissue regions. The gene discussed is WFDC2; the disease is ovarian carcinoma.